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Studies using chemical inhibitors have suggested that p38 MAP kinase is a key regulator of Wnt/b-catenin
signaling. In this issue, Verkaar et al. (2011) show that cross-reactivity of p38 inhibitors with casein kinase
Id/3 is responsible for Wnt/b-catenin pathway inhibition.Wnt proteins are members of an evolu-
tionarily conserved family of signaling
molecules that play a central role in
embryonic development and adult tissue
homeostasis (Logan and Nusse, 2004).
Given this wide array of functions, it is
not surprising that the deregulation of
Wnt signaling is associated with a range
of human diseases (Clevers, 2006); chief
among these is cancer, providing a major
incentive to define the molecular mecha-
nism ofWnt signaling and to find inhibitors
that can be used to target the Wnt
pathway in cancer treatment.
In recent years, a detailed outline of the
Wnt signaling mechanism has emerged.
Wnt can signal through several distinct
pathways, but the major pathway related
to stem cell maintenance and cancer is
the so-called canonical Wnt/b-catenin
pathway (MacDonald et al., 2009). A
central player in this pathway is b-catenin,
which interacts with TCF transcription
factors to co-activate the expression of
Wnt target genes. In the absence of
theWnt ligand, b-catenin levels are down-
regulated by a destruction complex that
consists of the scaffold protein Axin, the
APC tumor suppressor protein, and the
kinases casein kinase Ia (CKIa) and
GSK3b, which phosphorylate b-catenin
to target it for proteasome-mediateddegradation. Binding of Wnt to its re-
ceptors Frizzled and LRP5/6 inhibits
destruction complex function, leading to
stabilization and translocationofb-catenin
to the nucleus. Although themechanismof
destruction complex inhibition is still
poorly understood, it is clear that phos-
phorylation of Disheveled (Dvl) by casein
kinase Id/3 (CKId/3) is an important step in
this process (Bryja et al., 2007; Gao et al.,
2002). Recently, the MAP kinase p38
has been implicated in Wnt/b-catenin
signaling as well (Bikkavilli et al., 2008).
To identify low molecular weight
compounds that inhibit the Wnt/b-catenin
pathway, Verkaar et al. (2011) developed
an elegant b-galactosidase complemen-
tation assay to detect translocation of
b-catenin into the nucleus. In the study
published in this issue of Chemistry &
Biology, they applied this method to
screena relatively small collectionofa little
over 2000 compounds and found that two
compounds, TAK-715 and AMG-548,
potently inhibit theWnt-dependent stabili-
zation of b-catenin (Verkaar et al., 2011).
TAK-715 and AMG-548 were previously
characterized as inhibitors of p38 MAP
kinase, which would be in agreement
with the reported role of p38 in the
Wnt/b-catenin pathway (Bikkavilli et al.,
2008). However, further characterizationof TAK-715 and AMG-548 using a panel
of kinases revealed that these com-
pounds also inhibit CKId/3. This finding
prompted the question of whether the
two compoundsmight inhibit Wnt/b-cate-
nin signaling through CKId/3 instead of
p38. Consistent with this notion, it was
found that selective p38 inhibitors that
do not cross-react with CKId/3 have no
effect on Wnt/b-catenin signaling, raising
doubts about the role of p38 in this
signaling pathway. Indeed, Verkaar et al.
(2011) found that knockdown of p38 did
not interfere with the Wnt-dependent
phosphorylation of Dvl, and that p38 was
not activated after Wnt stimulation.
This study has several important impli-
cations. First, it shows that results ob-
tained with kinase inhibitors should be
interpreted with caution and that potential
cross-reactivity with other kinases should
be rigorously tested. Second, the study
provides compelling evidence that p38
MAP kinase is not involved in Wnt/b-
catenin signaling. Finally, TAK-715 and
AMG-548 are clinically evaluated com-
pounds that can now be repositioned for
the treatment of Wnt-dependent tumors.
As TAK-715 and AMG-548 target the
Wnt pathway at the level of CKId/3, it is
unlikely that they will be effective in tumors
harboring mutations in downstreamª2011 Elsevier Ltd All rights reserved 409
Chemistry & Biology
Previewscomponents such as APC. It is becoming
clear, however, that a wide range of
cancers activate Wnt signaling by epige-
neticdownregulationof secretedWnt inhib-
itors such as Dkk1, WIF1, and members of
the secreted Frizzled-related family (Ying
and Tao, 2009). Especially in these cases,
CKId/3 inhibitors such as TAK-715 and
AMG-548 may prove to be therapeutically
important.410 Chemistry & Biology 18, April 22, 2011 ªREFERENCES
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An audacious bet on transforming histone H4 into a real-time sensor probe has been won by the group of
Minoru Yoshida, who designed the first FRET probes capable of signaling the occurrence of dynamic site-
specific acetylations in live cells.Analyzing and understanding the func-
tional significance of genome signposting
by covalent modifications of DNA and
histones constitutes a real challenge in
modern biology. An important feature of
these signs is their dynamic nature, which
correlates with their potential to act as
a support for the so-called heritable
epigenetic information. The precise vision
of these dynamic alterations of DNA and
histones is critical to fully understanding
the epigenome and its regulatory circuits.
The advent of live cell imaging and
fluorescent probes is now allowing the
design of experimental approaches to
achieve this goal. Our increasing knowl-
edge of cellular machineries capable
of recognizing DNA methylation and
specific histone posttranslational modifi-
cations (PTM) has opened the way for
the design of fluorescent protein-based
probes bearing specific binding domains
of the corresponding factors and antibody
fragments capable of recognizing specific
modifications. Several FRET probes were
also conceived using a combination of
a histone PTM-binding element and ahistone fragment capable of receiving
the PTM (Kimura et al., 2010). These
approaches had two major limitations.
The first was that the probes needed to
access their targets to generate meaning-
ful signals, therefore creating a depen-
dency on the state of chromatin and site
accessibility. The second limitation was
the inability of fusions comprising histone
fragments to integrate chromatin, making
them insensitive to chromatin-dependent
events.
The design of a probe capable of being
assembled into chromatin (in other words,
a histone-sensor of PTMs) therefore
appeared as an elegant way to circum-
vent these problems. However, feasibility
issues hit the attractiveness of the idea
and could have stopped many from
trying. The group of Minoru Yoshida
started the adventure by using a full-
length histone H4 as a building basis for
a histone-probe molecule. The aim was
to develop a sensor of H4 acetylation by
using an already characterized bromodo-
main-containing protein, fused to the
N-terminal of the histone and separatedfrom it by a flexible linker peptide. Two
GFP-derived proteins (Venus and CFP)
were also fused on either side of the re-
sulting protein in order to generate a full-
length probe susceptible of reporting a
FRET signal after an acetylation-depen-
dent conformation change (Sasaki et al.,
2009; Ito et al., 2011).
Outstandingly, this fusion protein is
recognized as a regular histone H4 by the
cellular chromatin assembly machinery
and is incorporated into chromatin, there-
fore giving the unprecedented power of
sensing the occurrence of an acetylation
event from the ‘‘inside’’ of a chromatin
fiber. The first probe, named Histac,
contained Brdt, a testis-specific double
bromodomain protein (Pivot-Pajot et al.,
2003) as the acetyl-recognition module.
One of the first pieces of information
revealed by the probe was the identity of
the acetyl-acceptor sites, recognized by
Brdt in living cells, as being lysine 5 and
8 (K5 and K8) on histone H4. The data
also indicated the requirement of the
simultaneous acetylation of H4K5 and
H4K8 for Brdt to bind (Sasaki et al.,
